E76 Disorders of glycosaminoglycan metabolism

Name of the Condition

• Disorders of Glycosaminoglycan Metabolism (ICD-10 Code: E76)

Summary

Disorders of glycosaminoglycan metabolism are a group of inherited conditions affecting the breakdown of glycosaminoglycans (GAGs), which are long chains of sugar molecules found in connective tissues. These disorders disrupt normal cellular function, leading to a range of systemic effects, including skeletal abnormalities, organ dysfunction, and neurological impairment. Early recognition and management are important to address complications.

Causes

The disorders are caused by genetic mutations that impair enzymes responsible for breaking down GAGs. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of glycosaminoglycan metabolism disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, or hearing loss.
• Respiratory or cardiac complications due to tissue accumulation.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, followed by biochemical testing to measure GAG levels in urine or blood. Enzyme assays or genetic testing may confirm specific enzyme deficiencies. Imaging studies (e.g., X-rays, MRI) can assess skeletal or organ involvement.

Treatment Options

Treatment is primarily supportive and may include enzyme replacement therapy for some subtypes, physical therapy to manage mobility, and medications to address specific symptoms (e.g., pain, seizures). Hematopoietic stem cell transplantation may be considered in select cases.

Prognosis and Follow-Up

Prognosis varies by subtype and severity, with some forms leading to progressive disability or reduced life expectancy. Regular monitoring of organ function, developmental progress, and treatment response is essential. Multidisciplinary care involving specialists in genetics, neurology, and orthopedics is often required.

Complications

• Progressive organ damage (e.g., liver, heart, or respiratory failure).
• Severe neurological decline or loss of motor function.
• Skeletal deformities requiring surgical intervention.
• Vision or hearing loss due to tissue accumulation.

Lifestyle & Prevention

• Genetic counseling for families with a history of these disorders.
• Prenatal testing or carrier screening in high-risk pregnancies.
• Supportive care to maintain mobility and quality of life, such as adaptive equipment or physical therapy.

When to Seek Professional Help

Seek medical attention if symptoms such as developmental delays, unexplained organ enlargement, or skeletal abnormalities are observed, especially in children. Early evaluation is critical for timely diagnosis and management.

Tips for Medical Coders

Document the specific subtype of glycosaminoglycan metabolism disorder when available, as coding may require additional specificity. Ensure clinical documentation supports the diagnosis, including enzyme assay results or genetic testing, to justify code assignment. Note that E76 is a broad category, and subtypes (e.g., mucopolysaccharidoses) may require more detailed coding.